IL17A and myeloid sarcoma: Interestingly, previous study demonstrated that the circulating levels of TNF-α and IL-17 were significantly increased in MS-affected patients compared to HCs [49], suggesting the significant reduction of plasma α-DIPA level might be one of causal factors evoking activation of IL-17 and TNF-α signaling in patients with MS.